

Stefano Bonini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6121975/publications.pdf>

Version: 2024-02-01

175
papers

10,644
citations

38720

50
h-index

37183

96
g-index

180
all docs

180
docs citations

180
times ranked

6834
citing authors

#	ARTICLE	IF	CITATIONS
1	TFOS DEWS II pathophysiology report. <i>Ocular Surface</i> , 2017, 15, 438-510.	2.2	1,049
2	Location and Clonal Analysis of Stem Cells and Their Differentiated Progeny in the Human Ocular Surface. <i>Journal of Cell Biology</i> , 1999, 145, 769-782.	2.3	657
3	AUTOLOGOUS FIBRIN-CULTURED LIMBAL STEM CELLS PERMANENTLY RESTORE THE CORNEAL SURFACE OF PATIENTS WITH TOTAL LIMBAL STEM CELL DEFICIENCY1. <i>Transplantation</i> , 2001, 72, 1478-1485.	0.5	458
4	Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 10955-10960.	3.3	382
5	Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic Ulcers. <i>New England Journal of Medicine</i> , 1998, 338, 1174-1180.	13.9	375
6	Vernal keratoconjunctivitis revisited. <i>Ophthalmology</i> , 2000, 107, 1157-1163.	2.5	371
7	Neurotrophic keratitis. <i>Eye</i> , 2003, 17, 989-995.	1.1	309
8	Topical treatment with nerve growth factor for neurotrophic keratitis. <i>Ophthalmology</i> , 2000, 107, 1347-1351.	2.5	262
9	Vernal keratoconjunctivitis. <i>Eye</i> , 2004, 18, 345-351.	1.1	211
10	Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. <i>Journal of Allergy and Clinical Immunology</i> , 1997, 100, 408-414.	1.5	206
11	Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13469-13474.	3.3	202
12	Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. <i>Ophthalmology</i> , 2018, 125, 1332-1343.	2.5	188
13	Nerve growth factor is preformed in and activates human peripheral blood eosinophils. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 454-460.	1.5	182
14	Diagnosing the severity of dry eye: a clear and practical algorithm. <i>British Journal of Ophthalmology</i> , 2014, 98, 1168-1176.	2.1	167
15	Alterations of Tear Neuromediators in Dry Eye Disease. <i>JAMA Ophthalmology</i> , 2011, 129, 981.	2.6	130
16	Clinical grading of vernal keratoconjunctivitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2007, 7, 436-441.	1.1	124
17	Biological parameters determining the clinical outcome of autologous cultures of limbal stem cells. <i>Regenerative Medicine</i> , 2013, 8, 553-567.	0.8	117
18	Management of neurotrophic keratopathy. <i>Current Opinion in Ophthalmology</i> , 1999, 10, 270-276.	1.3	102

#	ARTICLE	IF	CITATIONS
19	Topical Treatment of Pressure Ulcers with Nerve Growth Factor. <i>Annals of Internal Medicine</i> , 2003, 139, 635.	2.0	100
20	Clinical impact of inflammation in dry eye disease: proceedings of the <scp>ODISSEY</scp> group meeting. <i>Acta Ophthalmologica</i> , 2018, 96, 111-119.	0.6	100
21	Allergen dose response and late symptoms in a human model of ocular allergy. <i>Journal of Allergy and Clinical Immunology</i> , 1990, 86, 869-876.	1.5	98
22	Nerve growth factor and tissue repair remodeling: trkANGFR and p75NTR, two receptors one fate. <i>Cytokine and Growth Factor Reviews</i> , 2007, 18, 245-256.	3.2	96
23	Nerve growth factor therapy for corneal disease. <i>Current Opinion in Ophthalmology</i> , 2012, 23, 296-302.	1.3	88
24	Effect of topical application of nerve-growth factor on pressure ulcers. <i>Lancet, The</i> , 1999, 354, 307.	6.3	87
25	The cellular mechanisms of dry eye: From pathogenesis to treatment. <i>Journal of Cellular Physiology</i> , 2013, 228, 2253-2256.	2.0	87
26	High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2015, 33, 110-112.	0.8	82
27	Effect of exogenous administration of nerve growth factor in the retina of rats with inherited retinitis pigmentosa. <i>Vision Research</i> , 2005, 45, 1491-1500.	0.7	79
28	Pharmacokinetics of Conjunctivally Applied Nerve Growth Factor in the Retina and Optic Nerve of Adult Rats. , 2005, 46, 3800.		78
29	Expression of Toll-like Receptors in Healthy and Allergic Conjunctiva. <i>Ophthalmology</i> , 2005, 112, 1528.e1-1528.e8.	2.5	77
30	Development and Testing of the Quality of Life in Children with Vernal Keratoconjunctivitis Questionnaire. <i>American Journal of Ophthalmology</i> , 2007, 144, 557-563.e2.	1.7	74
31	Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with vernal keratoconjunctivitis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 435-441.	1.0	74
32	Animal models of allergic and inflammatory conjunctivitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 1101-1113.	2.7	73
33	Nerve Growth Factor Promotes Corneal Epithelial Migration by Enhancing Expression of Matrix Metalloprotease-9. , 2013, 54, 3880.		70
34	Corneal Changes in Neurosurgically Induced Neurotrophic Keratitis. <i>JAMA Ophthalmology</i> , 2013, 131, 1547.	1.4	70
35	Estrogen and Progesterone Receptors in Vernal Keratoconjunctivitis. <i>Ophthalmology</i> , 1995, 102, 1374-1379.	2.5	69
36	Allergic chronic inflammation of the ocular surface in vernal keratoconjunctivitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2003, 3, 381-387.	1.1	69

#	ARTICLE	IF	CITATIONS
37	Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2005, 243, 151-155.	1.0	66
38	A Randomized Study of the Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in Treatment of Moderate to Severe Dry Eye. <i>European Journal of Ophthalmology</i> , 2017, 27, 520-530.	0.7	65
39	Conjunctival hyperresponsiveness to ocular histamine challenge in patients with vernal conjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 1992, 89, 103-107.	1.5	64
40	Prospective, Multicenter Demographic and Epidemiological Study on Vernal Keratoconjunctivitis: A Glimpse of Ocular Surface in Italian Population. <i>Ophthalmic Epidemiology</i> , 2009, 16, 38-41.	0.8	64
41	Chemokine Receptor CCR5 Expression in Conjunctival Epithelium of Patients With Dry Eye Syndrome. <i>JAMA Ophthalmology</i> , 2006, 124, 710.	2.6	63
42	The eosinophil and the eye. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1997, 52, 44-47.	2.7	62
43	Nerve growth factor effect on human primary fibroblastic-keratocytes: Possible mechanism during corneal healing. <i>Experimental Eye Research</i> , 2006, 83, 747-757.	1.2	62
44	Retinal p75 and bax overexpression is associated with retinal ganglion cells apoptosis in a rat model of glaucoma. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 1743-1749.	1.0	61
45	Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. <i>British Journal of Ophthalmology</i> , 2007, 91, 1656-1661.	2.1	60
46	Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseases. <i>Cytokine and Growth Factor Reviews</i> , 2004, 15, 411-417.	3.2	57
47	Clinical and cytological findings in limbal stem cell deficiency. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2005, 243, 870-876.	1.0	57
48	Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. <i>Ophthalmology</i> , 2018, 125, 1468-1471.	2.5	56
49	The ocular microbiome and microbiota and their effects on ocular surface pathophysiology and disorders. <i>Survey of Ophthalmology</i> , 2021, 66, 907-925.	1.7	56
50	Do sex and hormonal status influence choroidal circulation?. <i>British Journal of Ophthalmology</i> , 2000, 84, 786-787.	2.1	54
51	In Vitro Evidence of Nerve Growth Factor Effects on Human Conjunctival Epithelial Cell Differentiation and Mucin Gene Expression. , 2009, 50, 4622.		54
52	In Vivo Characterization of Doxycycline Effects on Tear Metalloproteinases in Patients with Chronic Blepharitis. <i>European Journal of Ophthalmology</i> , 2009, 19, 708-716.	0.7	54
53	Tailored Approach to the Treatment of Vernal Keratoconjunctivitis. <i>Ophthalmology</i> , 2010, 117, 1294-1299.	2.5	54
54	Clinical applications of NGF in ocular diseases. <i>Archives Italiennes De Biologie</i> , 2011, 149, 283-92.	0.1	54

#	ARTICLE	IF	CITATIONS
55	Neurogenic inflammation of the ocular surface. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2010, 10, 498-504.	1.1	52
56	Conjunctival Provocation Test as a Model for the Study of Allergy and Inflammation in Humans. <i>International Archives of Allergy and Immunology</i> , 1989, 88, 144-148.	0.9	51
57	Vernal Keratoconjunctivitis: A Model of 5q Cytokine Gene Cluster Disease. <i>International Archives of Allergy and Immunology</i> , 1995, 107, 95-98.	0.9	50
58	Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2%-Induced Ocular Allergy. <i>Journal of Glaucoma</i> , 2004, 13, 163-167.	0.8	50
59	Exploring Serum Levels of Brain Derived Neurotrophic Factor and Nerve Growth Factor Across Glaucoma Stages. <i>PLoS ONE</i> , 2017, 12, e0168565.	1.1	50
60	Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 1350-1355.	1.5	49
61	Efficacy of Lodoxamide Eye Drops on Mast Cells and Eosinophils after Allergen Challenge in Allergic Conjunctivitis. <i>Ophthalmology</i> , 1997, 104, 849-853.	2.5	49
62	Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. <i>British Journal of Ophthalmology</i> , 2014, 98, 1016-1022.	2.1	48
63	Nerve growth factor eye drop administrated on the ocular surface of rodents affects the nucleus basalis and septum: Biochemical and structural evidence. <i>Brain Research</i> , 2007, 1127, 45-51.	1.1	47
64	Itchy-Dry Eye Associated with Polycystic Ovary Syndrome. <i>American Journal of Ophthalmology</i> , 2007, 143, 763-771.e2.	1.7	45
65	Toll-like receptors in ocular surface diseases: overview and new findings. <i>Clinical Science</i> , 2011, 120, 441-450.	1.8	45
66	Nerve growth factor and the immune system: old and new concepts in the cross-talk between immune and resident cells during pathophysiological conditions. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2004, 4, 425-430.	1.1	44
67	Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 896-897.e9.	1.5	43
68	Hormones and dry eye syndrome. <i>Current Opinion in Ophthalmology</i> , 2013, 24, 348-355.	1.3	42
69	Increased Serum Levels of Eosinophil Cationic Protein and Eosinophil-derived Neurotoxin (protein X) in Vernal Keratoconjunctivitis. <i>Ophthalmology</i> , 1994, 101, 1808-1811.	2.5	40
70	Vernal Keratoconjunctivitis-like Disease in Adults. <i>American Journal of Ophthalmology</i> , 2013, 155, 796-803.	1.7	40
71	Effectiveness of nedocromil sodium 2% eyedrops on clinical symptoms and tear fluid cytology of patients with vernal conjunctivitis. <i>Eye</i> , 1992, 6, 648-652.	1.1	39
72	Capsaicin-Induced Corneal Sensory Denervation and Healing Impairment Are Reversed by NGF Treatment. , 2012, 53, 8280.		39

#	ARTICLE	IF	CITATIONS
73	<i>In vivo</i> corneal confocal microscopy as a novel non-invasive tool to investigate cardiac autonomic neuropathy in Type 1 diabetes. <i>Diabetic Medicine</i> , 2015, 32, 262-266.	1.2	39
74	The Intriguing Role of Neuropeptides at the Ocular Surface. <i>Ocular Surface</i> , 2017, 15, 2-14.	2.2	39
75	Neutrophil and eosinophil participation in atopic and vernal keratoconjunctivitis. <i>Current Eye Research</i> , 2003, 26, 319-325.	0.7	38
76	Age-Related Changes to Human Tear Composition. , 2018, 59, 2024.		38
77	Montelukast, a Leukotriene Receptor Antagonist, in Vernal Keratoconjunctivitis Associated With Asthma. <i>JAMA Ophthalmology</i> , 2003, 121, 615.	2.6	37
78	The pro-fibrogenic effect of nerve growth factor on conjunctival fibroblasts is mediated by transforming growth factor-beta. <i>Clinical and Experimental Allergy</i> , 2005, 35, 650-656.	1.4	37
79	Topical Azithromycin as a Novel Treatment for Ocular Rosacea. <i>Ocular Immunology and Inflammation</i> , 2013, 21, 371-377.	1.0	37
80	Human Idiopathic Epiretinal Membranes Express NGF and NGF Receptors. <i>Retina</i> , 2008, 28, 628-637.	1.0	36
81	Molecular and cellular biomarkers in dry eye disease and ocular allergy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 523-533.	1.1	36
82	The Effect of an Artificial Tear Combining Hyaluronic Acid and Tamarind Seeds Polysaccharide in Patients with Moderate Dry Eye Syndrome: A New Treatment for Dry Eye. <i>European Journal of Ophthalmology</i> , 2014, 24, 173-178.	0.7	36
83	Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. , 2003, 241, 192-195.		35
84	Ocular surface damage by ophthalmic compounds. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2011, 11, 464-470.	1.1	35
85	Tear levels of neuropeptides increase after specific allergen challenge in allergic conjunctivitis. <i>Molecular Vision</i> , 2011, 17, 47-52.	1.1	35
86	NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies. <i>Pharmacological Research</i> , 2007, 56, 65-69.	3.1	34
87	Conjunctival mucin deficiency in complete androgen insensitivity syndrome (CAIS). <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 899-902.	1.0	34
88	Multiple action agents and the eye: do they really stabilize mast cells?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 454-465.	1.1	33
89	InflammAging at Ocular Surface: Clinical and Biomolecular Analyses in Healthy Volunteers. , 2019, 60, 1769.		32
90	Nerve Growth Factor (NGF): An Important Molecule for Trophism and Healing of the Ocular Surface. <i>Advances in Experimental Medicine and Biology</i> , 2002, 506, 531-537.	0.8	32

#	ARTICLE	IF	CITATIONS
91	Molecular basis for keratoconus: Lack of TrkA expression and its transcriptional repression by Sp3. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16795-16800.	3.3	31
92	The role of neuromediators in ocular allergy. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 466-471.	1.1	31
93	Neurotrophic keratopathy: Pros and cons of current treatments. Ocular Surface, 2019, 17, 619-623.	2.2	30
94	MUC5AC overexpression in tear film of neonates. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1377-1381.	1.0	29
95	Ocular Toxicity Related to Cetuximab Monotherapy in an Advanced Colorectal Cancer Patient. Journal of the National Cancer Institute, 2005, 97, 606-607.	3.0	27
96	Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa. BioMed Research International, 2015, 2015, 1-8.	0.9	26
97	Corneal angiogenic privilege and its failure. Experimental Eye Research, 2021, 204, 108457.	1.2	25
98	Challenges in Acanthamoeba Keratitis: A Review. Journal of Clinical Medicine, 2021, 10, 942.	1.0	25
99	Intraocular production and release of nerve growth factor after iridectomy. Investigative Ophthalmology and Visual Science, 2002, 43, 2334-40.	3.3	25
100	Late-phase reaction in topically induced ocular anaphylaxis in the rat. Current Eye Research, 1988, 7, 437-443.	0.7	24
101	Ocular surface diabetic disease: A neurogenic condition?. Ocular Surface, 2021, 19, 218-223.	2.2	24
102	Clinical trials in allergic conjunctivitis: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 919-924.	2.7	23
103	Sex Hormones in Allergic Conjunctivitis: Altered Levels of Circulating Androgens and Estrogens in Children and Adolescents with Vernal Keratoconjunctivitis. Journal of Immunology Research, 2015, 2015, 1-6.	0.9	23
104	Effects of Sex Hormones on Ocular Surface Epithelia: Lessons Learned From Polycystic Ovary Syndrome. Journal of Cellular Physiology, 2016, 231, 971-975.	2.0	22
105	The challenging management of pediatric corneal transplantation: an overview of surgical and clinical experiences. Japanese Journal of Ophthalmology, 2017, 61, 207-217.	0.9	22
106	Tears and ocular surface disorders: Usefulness of biomarkers. Journal of Cellular Physiology, 2019, 234, 9982-9993.	2.0	22
107	T-helper 17 lymphocytes in ocular cicatricial pemphigoid. Molecular Vision, 2009, 15, 1449-55.	1.1	22
108	Limbal Stem Cell Deficiency Associated With LADD Syndrome. JAMA Ophthalmology, 2005, 123, 691.	2.6	21

#	ARTICLE	IF	CITATIONS
109	The Eosinophil Has a Pivotal Role in Allergic Inflammation of the Eye. <i>International Archives of Allergy and Immunology</i> , 1992, 99, 354-358.	0.9	20
110	A simple and rapid diagnostic algorithm for the detection of ocular allergic diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 471-476.	1.1	20
111	Cocaine snorting may induce ocular surface damage through corneal sensitivity impairment. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2015, 253, 765-772.	1.0	20
112	Toll-Like Receptors and Tissue Remodeling: The Pro/Cons Recent Findings. <i>Journal of Cellular Physiology</i> , 2016, 231, 531-544.	2.0	20
113	Nerve growth factor eye drops to treat glaucoma. <i>Drug News and Perspectives</i> , 2010, 23, 361.	1.9	20
114	Natural killer cells in vernal keratoconjunctivitis. <i>Molecular Vision</i> , 2007, 13, 1562-7.	1.1	20
115	Hyperosmolar conjunctival provocation for the evaluation of nonspecific hyperreactivity in healthy patients and patients with allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 872-877.	1.5	19
116	Topical treatment with nerve growth factor in an animal model of herpetic keratitis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 246, 121-127.	1.0	19
117	Nerve growth factor has a modulatory role on human primary fibroblast cultures derived from vernal keratoconjunctivitis-affected conjunctiva. <i>Molecular Vision</i> , 2007, 13, 981-7.	1.1	19
118	Cytokines in Ocular Allergy. <i>International Ophthalmology Clinics</i> , 2003, 43, 27-32.	0.3	18
119	HLA-B5 and Behçet's Disease. <i>Tissue Antigens</i> , 1979, 14, 444-448.	1.0	18
120	Chronic Nerve Growth Factor Exposure Increases Apoptosis in a Model of In Vitro Induced Conjunctival Myofibroblasts. <i>PLoS ONE</i> , 2012, 7, e47316.	1.1	18
121	NGF Modulates trkA/NGFR/p75NTR in α -SMA-Expressing Conjunctival Fibroblasts from Human Ocular Cicatricial Pemphigoid (OCP). <i>PLoS ONE</i> , 2015, 10, e0142737.	1.1	18
122	Quiescent and Active Tear Protein Profiles to Predict Vernal Keratoconjunctivitis Reactivation. <i>BioMed Research International</i> , 2016, 2016, 1-10.	0.9	17
123	Inflammatory Stress Causes N-Glycan Processing Deficiency in Ocular Autoimmune Disease. <i>American Journal of Pathology</i> , 2019, 189, 283-294.	1.9	17
124	Endoplasmic reticulum stress promotes inflammation-mediated proteolytic activity at the ocular surface. <i>Scientific Reports</i> , 2020, 10, 2216.	1.6	16
125	The Anti-Inflammatory Effects of Therapies for Ocular Allergy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 786-793.	0.6	15
126	Review: Environmental impact on ocular surface disorders: Possible epigenetic mechanism modulation and potential biomarkers. <i>Ocular Surface</i> , 2017, 15, 680-687.	2.2	15

#	ARTICLE	IF	CITATIONS
127	Nerve growth factor modulates toll-like receptor (TLR) 4 and 9 expression in cultured primary VKC conjunctival epithelial cells. <i>Molecular Vision</i> , 2009, 15, 2037-44.	1.1	15
128	Is visual function affected in severe ocular allergies?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2013, 13, 558-562.	1.1	14
129	Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 670-677.	0.6	14
130	Review article: Mucosa-associated lymphoid tissue (MALT)-type lymphoma of ocular adnexa. <i>Biology and treatment. Critical Reviews in Oncology/Hematology</i> , 2016, 100, 37-45.	2.0	13
131	Adult vernal keratoconjunctivitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 501-506.	1.1	13
132	Does Endogenous Endophthalmitis Need a More Aggressive Treatment?. <i>Ocular Immunology and Inflammation</i> , 2020, , 1-7.	1.0	12
133	Tear film and ocular surface neuropeptides: Characteristics, synthesis, signaling and implications for ocular surface and systemic diseases. <i>Experimental Eye Research</i> , 2022, 218, 108973.	1.2	12
134	Basophil Histamine Release and Leukotriene (LTB4 - LTC4) Production in Cluster Headache. <i>Headache</i> , 1989, 29, 46-48.	1.8	11
135	Nerve growth factor (NGF) and lenses: effects of NGF in an in vitro rat model of cataract. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2003, 241, 845-851.	1.0	11
136	Therapeutic Effect of Topical 5-Fluorouracil in Conjunctival Squamous Carcinoma Is Associated With Changes in Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Expression. <i>Cornea</i> , 2009, 28, 821-824.	0.9	11
137	Ocular prostheses in the last century: a retrospective analysis of 8018 patients. <i>Eye</i> , 2013, 27, 865-870.	1.1	11
138	Management of Porous Orbital Implants Requiring Explantation. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2014, 30, 132-136.	0.4	11
139	TFOS European Ambassador meeting: Unmet needs and future scientific and clinical solutions for ocular surface diseases. <i>Ocular Surface</i> , 2020, 18, 936-962.	2.2	11
140	The survival analysis approach in Basel II credit risk management: modeling danger rates in the loss given default parameter. <i>Journal of Credit Risk</i> , 2013, 9, 101-118.	0.2	11
141	Late-phase reaction and tear fluid cytology in the rat ocular anaphylaxis. <i>Current Eye Research</i> , 1987, 6, 659-665.	0.7	10
142	The Early and Late Phase of the Ocular Allergic Reaction. <i>Acta Ophthalmologica</i> , 2000, 78, 41-41.	0.4	10
143	Nerve growth factor modulates in vitro the expression and release of TGF- β 1 by amniotic membrane. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 485-491.	1.0	10
144	Adult Vernal Keratoconjunctivitis: Clinical and biochemical profile of a rare disease. <i>Ocular Surface</i> , 2019, 17, 737-742.	2.2	10

#	ARTICLE	IF	CITATIONS
145	Acanthamoeba Keratitis: Perspectives for Patients. <i>Current Eye Research</i> , 2021, 46, 771-776.	0.7	10
146	Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease. <i>Frontiers in Pharmacology</i> , 2020, 11, 601647.	1.6	10
147	Age-related ocular surface failure: A narrative review. <i>Experimental Eye Research</i> , 2022, 219, 109035.	1.2	8
148	Toxic corneal ulcer: a frequent and sight-threatening disease. <i>European Journal of Ophthalmology</i> , 2009, 19, 916-922.	0.7	7
149	Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitumumab. <i>International Journal of Colorectal Disease</i> , 2009, 24, 1247-1248.	1.0	7
150	Preliminary evidence of neuropeptides involvement in keratoconus. <i>Acta Ophthalmologica</i> , 2015, 93, e315-6.	0.6	7
151	Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis. <i>Eye</i> , 1996, 10, 422-424.	1.1	6
152	Allergic Conjunctivitis: Update on Its Pathophysiology and Perspectives for Future Treatment. , 2009, , 25-48.		6
153	The pattern of the ocular late phase reaction induced by allergen challenge in hay fever conjunctivitis. <i>Ocular Immunology and Inflammation</i> , 1994, 2, 191-197.	1.0	5
154	Estimating loss-given default through advanced credibility theory. <i>European Journal of Finance</i> , 2016, 22, 1351-1362.	1.7	5
155	Mast Cells Populate the Corneoscleral Limbus: New Insights for Our Understanding of Limbal Microenvironment. , 2020, 61, 43.		5
156	The red eye. <i>European Journal of Ophthalmology</i> , 2021, 31, 2843-2849.	0.7	5
157	Effect of minimonovision in bilateral implantation of a novel non-diffractive extended depth-of-focus intraocular lens: Defocus curves, visual outcomes, and quality of life. <i>European Journal of Ophthalmology</i> , 2022, 32, 2942-2948.	0.7	5
158	Passive transfer of the ocular late-phase reaction. <i>Ocular Immunology and Inflammation</i> , 1993, 1, 323-325.	1.0	4
159	Vernal Keratoconjunctivitis (VKC). <i>Ocular Immunology and Inflammation</i> , 1993, 1, 13-17.	1.0	4
160	Molecular and biochemical expression of TLRs in human amniotic membrane: a comparative study of fresh and cryopreserved specimens. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 267-274.	1.0	4
161	<p>Lamellar macular holes: monitoring and management strategies</p>. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 1173-1182.	0.9	4
162	Effects of topical pre-treatment with dexamethasone on the immediate and late phases of topically induced ocular anaphylaxis in the rat. <i>Acta Ophthalmologica</i> , 1988, 66, 24-32.	0.6	3

#	ARTICLE	IF	CITATIONS
163	Current and emerging treatment options for vernal keratoconjunctivitis. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 343-353.	0.5	3
164	Fc- γ RIII/CD23 Receptor on Circulating Human Eosinophils. <i>Blood</i> , 1998, 91, 2621-2622.	0.6	2
165	Nerve Growth Factor in Behçet's Disease. , 2003, 528, 283-285.		2
166	Development of a LGD Model Basel2 Compliant: A Case Study. , 2014, , 45-48.		2
167	Should we care about the ocular surface in the anophthalmic patient?. <i>European Journal of Ophthalmology</i> , 2021, , 112067212110488.	0.7	2
168	Genetics of Ocular Allergy. <i>Acta Ophthalmologica</i> , 1999, 77, 31-32.	0.4	1
169	Beyond Basel2: Modeling loss given default through survival analysis. , 2012, , 43-52.		1
170	Allergic eye disease: Blocking LTB4/C5 in vivo suppressed disease and Th2 & Th9 cells. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 660-664.	2.7	1
171	Intraocular Pressure Peaks. <i>Ophthalmology</i> , 1991, 98, 1323.	2.5	0
172	Targets in Ocular Allergy. , 2005, , 1-9.		0
173	Ocular allergies in 2005. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 179-181.	1.3	0
174	Reply. <i>Ophthalmology</i> , 2019, 126, e15-e16.	2.5	0
175	Artificial Intelligence: the Application of Machine Learning and Predictive Analytics in Credit Risk. <i>Risk Management Magazine</i> , 2021, 16, 19-29.	0.2	0